184576-15-6

Basic information

• Product Name: tert-butyl 2-[(3S)-4-[(2S)-2-[(benzyloxycarbonyl)amino]-3-(4-methoxyphenyl)propanoyl]-3-[4-[(tert-butoxycarbonyl)amino]butyll]-2-oxopiperazinyl]acetate
• Synonyms: tert-butyl 2-[(3S)-4-[(2S)-2-[(benzyloxycarbonyl)amino]-3-(4-methoxyphenyl)propanoyl]-3-[4-[(tert-butoxycarbonyl)amino]butyll]-2-oxopiperazinyl]acetate
• CAS NO: 184576-15-6
• Molecular Weight: 696.841
• Mol File: 184576-15-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: tert-butyl 2-[(3S)-4-[(2S)-2-[(benzyloxycarbonyl)amino]-3-(4-methoxyphenyl)propanoyl]-3-[4-[(tert-butoxycarbonyl)amino]butyll]-2-oxopiperazinyl]acetate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-[(3S)-4-[(2S)-2-[(benzyloxycarbonyl)amino]-3-(4-methoxyphenyl)propanoyl]-3-[4-[(tert-butoxycarbonyl)amino]butyll]-2-oxopiperazinyl]acetate(184576-15-6)
• EPA Substance Registry System: tert-butyl 2-[(3S)-4-[(2S)-2-[(benzyloxycarbonyl)amino]-3-(4-methoxyphenyl)propanoyl]-3-[4-[(tert-butoxycarbonyl)amino]butyll]-2-oxopiperazinyl]acetate(184576-15-6)

Safety Data

• Hazardous Substances Data: 184576-15-6(Hazardous Substances Data)

Upstream product

• 17554-34-6 (2S)-2-[(benzyloxycarbonyl)amino]-3-(4-methoxyphenyl)propanoic acid 
• 184576-11-2 tert-butyl 2-[(3S)-3-[4-[(tert-butoxycarbonyl)amino]butyl]-2-oxopiperazinyl]acetate 
• 1027172-04-8 2-(4-tert-butoxycarbonylamino-butyl)-4-tert-butoxycarbonylmethyl-3-oxo-3,4-dihydro-2H-pyrazine-1-carboxylic acid benzyl ester 

Relevant articles and documents

Potent dibasic GPIIb/IIIa antagonists with reduced prolongation of bleeding time: Synthesis and pharmacological evaluation of 2-oxopiperazine derivatives

A series of 2-oxopiperazine derivatives, possessing basic moieties at the 3- and the 4-positions, were synthesized and evaluated for their abilities to inhibit platelet aggregation and for their effects on bleeding time. Among the compounds, 2-[(3S)-4-[2-[(4-guanidinobenzoyl)amino] acetyl]3-[3-[(4-guanidinobenzoyl)amino]propyl]-2-oxopiperazinyl]acetic acid (12c) showed a potent inhibitory effect on platelet aggregation and good dissociation between the efficacy and the bleeding side effect. Intravenous infusion of compound 12c at 1.6 μg/mL/min. completely prevented arterial thrombus formation induced by endothelial injury in guinea pigs. The dose of 12c that prolonged the bleeding time to three times the control value was 5.8/μg/mL/min. These results suggest that compound 12c might be useful in the clinical treatment of thrombotic diseases, and we selected 12c (TAK-024) as a candidate for the clinical trials.